Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Farez MF, Correale J, Armstrong MJ, Rae-Grant A, Gloss D, Donley D, Holler-Managan Y, Kachuck NJ, Jeffery D, Beilman M, Gronseth G, Michelson D, Lee E, Cox J, Getchius T, Sejvar J, Narayanaswami P.

Neurology. 2019 Sep 24;93(13):584-594. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.

PMID:
31462584
2.
3.

Registries, research, and regrets: is the FDA's post-marketing REMS process not adequately protecting patients?

Kachuck NJ.

Ther Adv Neurol Disord. 2011 Nov;4(6):339-47. doi: 10.1177/1756285611424461. No abstract available.

5.

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis.

Kachuck NJ.

Neuropsychiatr Dis Treat. 2011;7:197-208. doi: 10.2147/NDT.S17522. Epub 2011 Apr 19.

6.

Managing conflicts of interest and commitment: academic medicine and the physician's progress.

Kachuck NJ.

J Med Ethics. 2011 Jan;37(1):2-5. doi: 10.1136/jme.2010.035832. No abstract available.

PMID:
21149321
7.

Ethical perspectives in neurology: ethical considerations when doctor and patient perspectives on treatment risks differ.

Conway J, Kachuck NJ.

Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):234-7. doi: 10.1212/01.CON.0000389947.12477.85. No abstract available.

PMID:
22810609
8.

Reframing the conflicts of interest debacle: academic medicine, the healing alliance and the physician's moral imperative.

Kachuck NJ.

J Med Ethics. 2009 Sep;35(9):526-7. doi: 10.1136/jme.2009.032110. No abstract available.

PMID:
19717688
9.

Sustained release oral fampridine in the treatment of multiple sclerosis.

Kachuck NJ.

Expert Opin Pharmacother. 2009 Aug;10(12):2025-35. doi: 10.1517/14656560903075994. Review. Erratum in: Expert Opin Pharmacother. 2009 Oct;10(14):2393.

PMID:
19586420
10.

Challenges and opportunities: what we are learning from the clinical natalizumab experience.

Kachuck NJ.

Expert Rev Neurother. 2005 Sep;5(5):605-15. Review.

PMID:
16162084
11.

Increased CXCL8 (IL-8) expression in Multiple Sclerosis.

Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP.

J Neuroimmunol. 2004 Oct;155(1-2):161-71.

PMID:
15342208
12.

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2003 Sep 9;61(5):602-11.

PMID:
12963748
13.

Immunological aspects of secondary progressive multiple sclerosis.

Weiner LP, Kachuck NJ, Gilmore W, Lund B.

Mult Scler. 2002 Feb;8(1):83-4. Review. No abstract available.

PMID:
11936493
14.

Characterization of monoclonal antibodies to human OC43.

Fleming JO, Keck JG, Wei T, Kachuck NJ, Stohlman SA.

Adv Exp Med Biol. 1987;218:517-20. No abstract available.

PMID:
3434439

Supplemental Content

Loading ...
Support Center